Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0XPKVR)
ADC Name
DM002
Synonyms
DM002; DM002 (Doma); BCG012
   Click to Show/Hide
Organization
Biocytogen (Originator);Sidao Medicine
Drug Status
Phase 1
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Anti-HER3/Muc1 bsAb
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-3 (HER3); Mucin-1 (MUC1)
  Antigen Info 
Payload Name
BCPT02
  Payload Info 
Payload Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Hydrophilic, protease-cleavable linker
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
BLD1102
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Unspecific solid tumor
1 Trials
Clinical trial identifier
NCT06751329; CTR20251053
2027 Update
ADC-specific functional property
Binding Affinity
Click To Hide/Show 1 ADC-specific functional property Data
Dissocation Constant (Kd) Binding Target Description Reference
10 nM
MUC1
DM002 is cross-reactive to human and cynomolgus monkey targets with an affinity (KD) of approximately 10-8 M.
[1]
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT06751329
PHASE1
A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Eligible patients (≥18 years, ECOG 0-2, life expectancy ≥3 months) must have measurable disease (RECIST 1.1), adequate organ function
Administration Dosage
An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
Related Clinical Trial
NCT Number NCT06751329  Clinical Status PHASE1
Clinical Description A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors
Primary Endpoint
Safety assessment includes DLT evaluation (grade 3 neurological/grade 4 toxicities) and MTD determination (0/3 or 1/6 DLT rate) for DM002 over 12 months.
Other Endpoint
PK parameters (AUC, Cmax, Tmax, Ctrough) and efficacy (ORR per RECIST 1.1) will be analyzed for 12 months.
References
Ref 1 1165 Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1
Ref 2 A Study of DM002 in Patients With Advanced Solid Tumors